Wedbush Reiterates Outperform on G1 Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has reiterated an Outperform rating on G1 Therapeutics (NASDAQ:GTHX) and maintained a $5 price target.
October 30, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst has reiterated an Outperform rating on G1 Therapeutics and maintained a $5 price target.
The reiteration of an Outperform rating by a reputable analyst like David Nierengarten from Wedbush is a positive signal for G1 Therapeutics. The maintained price target of $5 also indicates a positive outlook for the stock. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100